Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Philippidis

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Human Gene Therapy|October 17, 2023
Up to $1.5B in Milestones as Otsuka, Shape Partner on Eye Disease Gene TherapiesAlex Philippidis
Human Gene Therapy|September 18, 2020
After Third Death, Audentes' AT132 Remains on Clinical HoldAlex Philippidis
Human Gene Therapy|June 20, 2023
Food and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene TherapyAlex Philippidis
Human Gene Therapy|March 24, 2020
FDA Prioritizes Biomarin's Hemophilia Gene TherapyAlex Philippidis
Human Gene Therapy|July 17, 2024
Pfizer Weighs Next Steps after DMD Therapy Linked to Boy's Death Fails Phase III TrialAlex Philippidis
Human Gene Therapy|July 18, 2023
Case Study Cites Immune Reaction to High Adeno-Associated Virus Dose in Explaining Duchenne Muscular Dystrophy Trial DeathAlex Philippidis
Human Gene Therapy|July 9, 2024
Boy Dosed with Pfizer's Duchenne Muscular Dystrophy Gene Therapy Dies a Year After Phase II TrialAlex Philippidis
Human Gene Therapy|September 23, 2021
After Sparring with Payers on Pricing, Bluebird Flies Out of EuropeAlex Philippidis
Human Gene Therapy|July 14, 2022
Astellas, REGENXBIO Open In-House Gene Therapy Manufacturing SitesAlex Philippidis
Human Gene Therapy|November 15, 2021
Takeda Doubles Down on Gene Therapy with Poseida, Selecta Collaborations Totaling $4.7BAlex Philippidis
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Human Gene Therapy|October 17, 2023
Up to $1.5B in Milestones as Otsuka, Shape Partner on Eye Disease Gene TherapiesAlex Philippidis
Human Gene Therapy|September 18, 2020
After Third Death, Audentes' AT132 Remains on Clinical HoldAlex Philippidis
Human Gene Therapy|June 20, 2023
Food and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene TherapyAlex Philippidis
Human Gene Therapy|March 24, 2020
FDA Prioritizes Biomarin's Hemophilia Gene TherapyAlex Philippidis
Human Gene Therapy|July 17, 2024
Pfizer Weighs Next Steps after DMD Therapy Linked to Boy's Death Fails Phase III TrialAlex Philippidis
Human Gene Therapy|July 18, 2023
Case Study Cites Immune Reaction to High Adeno-Associated Virus Dose in Explaining Duchenne Muscular Dystrophy Trial DeathAlex Philippidis
Human Gene Therapy|July 9, 2024
Boy Dosed with Pfizer's Duchenne Muscular Dystrophy Gene Therapy Dies a Year After Phase II TrialAlex Philippidis
Human Gene Therapy|September 23, 2021
After Sparring with Payers on Pricing, Bluebird Flies Out of EuropeAlex Philippidis
Human Gene Therapy|July 14, 2022
Astellas, REGENXBIO Open In-House Gene Therapy Manufacturing SitesAlex Philippidis
Human Gene Therapy|November 15, 2021
Takeda Doubles Down on Gene Therapy with Poseida, Selecta Collaborations Totaling $4.7BAlex Philippidis
Pageof 11